Phase II Trial Shows Benefit with Imbruvica in Activated B-cell-like Subtype of DLBCL

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

A phase II clinical trial identified patients with a specific molecular subtype of diffuse large B-cell lymphoma that are more likely to respond to Imbruvica (ibrutinib) treatment.

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe

YOU MAY BE INTERESTED IN

Login